a truly integrated drug discovery company 26 th April 2016 CONFIDENTIAL

Company Overview Founded in 2004 in BioCity Nottingham Integrated drug discovery company Strong demand for integrated expertise with >400% increase in revenues over past 6 years Privately owned by senior management and founding scientists  No external funding, no debt and profitable  Profits fund company’s growth and investment in the future

CONFIDENTIAL Seven Modern Well-Equipped Laboratories Functionally-mixed occupation for maximal interaction

CONFIDENTIAL Broad Drug Discovery Experience Therapeutic Areas Anti-infectives Cancer CNS Inflammation Metabolic disease Opthalmology Orphan indications Respiratory Biological Targets Epigenetic GPCRs Ion channels Kinases Nuclear hormone receptors Proteases Protein – protein interactions

CONFIDENTIAL 12 Years of Drug Discovery Success 144 full-time employees (and recruiting):  78 medicinal chemists  29 in vitro bioscientists  7 computational scientists  9 DMPK scientists  Dynamic mix of youth and experience  Scientists recruited from across the world o EU, USA, India, China, Japan etc Consistent track record of delivering success:  7 compounds currently in the clinic  15 compounds in pre-clinical development  >50 patents  >170 client projects delivered

CONFIDENTIAL Factors Contributing To Our Success Efficient Communication: Internal  Co-location facilitates clear communication of key issues and promotes problem-solving  All under one roof to provide rapid in vitro data generation and discussion External  Cloud-based informatics and ELNs ensure rapid dissemination of data to all parties  Constant client-focused interactions to agree most effective routes forward  Full-time dedicated experienced Project Leaders (lab-based scientists) Experience Counts: Tailored assay and reagent development Assay validity and reliability Rapid identification of efficient medicinal chemistry routes Interpretation of data generated

CONFIDENTIAL Project teams composed of problem-solving PhD medicinal chemists Extensive industry experience across a wide range of therapeutic areas Seamless integration with comp chem, bioscience and DMPK for optimal turnaround of design → make → test → analyse cycle First-class laboratory facilities and capabilities HTS / fragment library design, synthesis and purification (~1K compounds per month)

CONFIDENTIAL Decades of experience in generating computational models that provide key insights into molecular optimisation challenges Close collaboration with medicinal chemists and each client Support drug discovery projects at all stages: target analysis, hit id, hit- to-lead and lead optimisation

CONFIDENTIAL Staffed by expert bioscientists, many with years of drug discovery experience gained in pharmaceutical research Considerable drug discovery experience with small molecules and biologicals across a broad range of therapeutic areas and biological target classes Expert at designing screening cascades, establishing and performing complex assays, e.g. biochemical, cellular and biophysical Flexibility to respond to changes in project demands

CONFIDENTIAL Protein Crystallography Affiliate company – strategic financial investment by Sygil Group Founded in 2015 at BioHub, Alderley Park Protein expression and production  Construct design, protein expression and protein purification  Supply in formats suitable for in vitro assays, HTS, biophysics assays, in vivo studies or X- ray crystallography  Expression in E.coli, baculovirus/insect cells and mammalian cells  Few millilitres to >20 litres X-ray crystallography  Sparse matrix crystallisation screens, along with relevant screens designed around any literature precedents  Tool compounds used to explore options for co-crystallisation  Initial hit may require further optimisation to improve size and quality of diffraction  Following X-ray data collection at the synchrotron, 3D structural representations are produced

CONFIDENTIAL Dedicated to understanding and optimising the absorption, distribution, metabolism and excretion of drug candidates Working in close partnership with clients and other Sygnature departments to provide successful optimisation strategies Extensive know-how and expertise to provide well validated assays and a comprehensive applied consultancy service for interpretation of in vitro ADME and in vivo PK data

CONFIDENTIAL The Future … Our new home from Q2 2017

CONFIDENTIAL Summary UK’s largest independent provider of integrated drug discovery resource and expertise Considerable scientific experience is co-located to efficiently provide rapid problem-solving input into clients’ drug discovery projects Technically-advanced capabilities Peer level scientific collaborations that deliver drug candidates in a timely fashion Excellent track record of success for clients  7 compounds currently in the clinic  15 compounds in pre-clinical development

CONFIDENTIAL